Progress, Potential, and Possibilities Podcast / Show · 2026-05-28 · 44 min
Send us Fan Mail What if the biggest problem in nuclear energy isn’t reactor technology…but paperwork, regulation, and institutional bottlenecks? Today we explore how AI could compress nuclear deployment timelines from decades to years. Kevin Kong is founder and CEO of Everstar ( ), a company building advanced AI reasoning systems designed to accelerate the deployment of nuclear power and modernize the infrastructure workflows surrounding the industry. Now when most people think about nuclear innovation, they think about reactors, fusion, uranium, or next-generation fuels. But Kevin and his team are focused on a very different problem - the massive institutional and cognitive bottlenecks that slow nuclear projects down. We’re talking about years of regulatory review, millions of pages of compliance documentation, fragmented engineering systems, workforce shortages, operational complexity, and the enormous burden of coordinating safety-critical infrastructure at scale.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
229. Climate Tech reinvented: from green molecules to green electrons - May26Redefining Energy · on Nuclear energy92 / 100
The Evolution and Impact of AI and Machine Learning Across IndustriesBeyond the Screen · on Artificial intelligence79 / 100
World's Leading Safe AI Expert: Superintelligence Will Change Everything & It's Closer Than You Think! - Dr. Craig A. KaplanFour Fs Podcast · on Artificial intelligence74 / 100
101: Rapid Transformation - AI, Psychedelics & Leadership with Dr Catriona WallaceHabits of Leadership · on Artificial intelligence73 / 100
Deep Tech Gold Rush: Smart Boom or Future Bust?Venture Unlocked · on Artificial intelligence71 / 100
From “What Is” to “What If” in ConstructionThe Power of Construction · on Artificial intelligence69 / 100Building the Internet of Medicine: How AI Could Transform Children's Healthcare | Dr. Timothy Chou - Founder, Pediatric Moonshot92 / 100The Blood Test That Could Change Cancer Treatment Forever | Eric Matthews - General Manager, Biopharma, Natera65 / 100How Female Biology Shapes Skin Disease Across a Lifetime | Dr. Doral Fredericks, PharmD, MBA - Vice President and Head of Global Medical Affairs and Outcomes Research, Organon56 / 10055 Years Without a Diagnosis | Can AI Solve The Undiagnosed Condition Blind Spot? | Haresh Patel - Founder and CEO, Sanare Health AI70 / 100How Regenerative Medicine Is Reinventing Breast Reconstruction | Dr. Claudia Chavez-Munoz, MD, PhD - Chief Scientific Officer and Co-Founder - Conexeu Sciences